ELCC 2026: First-Line Immunotherapy in High PD-L1 Lung Cancer

Andreas Ravn Andersen, MD, PhD Fellow at Rigshospitalet, Denmark, presented a Danish real-world cohort study at the ELCC 2026 Congress comparing pembrolizumab and atezolizumab as first-line treatment in patients with high PD-L1 expression. The study, based on data from two Danish regions, found significantly lower overall survival with atezolizumab in the capital region, while no difference was observed in the central region. National data supported these findings, highlighting regional variability.